Completed PHASE3 INTERVENTIONAL 4-arm NCT05091307

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older

Sponsor: Janssen Vaccines & Prevention B.V.

Conditions COVID-19 Prevention

Interventions Ad26.COV2.S Influenza Vaccine Placebo

Updated 22 times since 2021 Last updated: May 22, 2025 Started: Nov 2, 2021 Primary completion: Jun 17, 2022 Completion: Nov 15, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on COVID-19 Prevention, this trial is completed. The trial is conducted by Janssen Vaccines & Prevention B.V. and has accumulated 22 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

22 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Jun 2025 — Sep 2025 [monthly]

Completed PHASE3
May 2025 — Jun 2025 [monthly]

Completed PHASE3
Apr 2025 — May 2025 [monthly]

Completed PHASE3
Mar 2025 — Apr 2025 [monthly]

Completed PHASE3

▶ Show 17 earlier versions

Sep 2024 — Mar 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2024 — Feb 2024 [monthly]

Completed PHASE3
Sep 2023 — Jan 2024 [monthly]

Completed PHASE3
Jun 2023 — Sep 2023 [monthly]

Completed PHASE3
Jan 2023 — Jun 2023 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Dec 2022 — Jan 2023 [monthly]

Active Not Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3
May 2022 — Jun 2022 [monthly]

Recruiting PHASE3
Mar 2022 — May 2022 [monthly]

Recruiting PHASE3
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE3
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Vaccines & Prevention B.V.

Data source: Janssen Vaccines & Prevention B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alken, Belgium , Antwerp, Belgium , Coral Gables, United States , Częstochowa, Poland , Evansville, United States , Fayetteville, United States , Fort Myers, United States , Gdansk, Poland , Gdynia, Poland , Hillsborough, United States and 18 more locations